Biosimilar Glargine Insulin: Implications for Prescribers and Patients

被引：1
|
作者：
Pereira, Katherine [1 ,2 ]
机构：
[1] Duke Univ, Sch Nursing Durham, Durham, NC 27708 USA
[2] Duke Univ, Sch Nursing Durham, Doctor Nursing Practice Program, Div Endocrinol Metab & Nutr, Durham, NC 27708 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2017年 / 13卷 / 03期
关键词：
FOLLOW-ON-BIOLOGICS; COMPETITION;
D O I：
10.1016/j.nurpra.2016.11.022
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：236 / 237
页数：2
相关论文
共 50 条
  • [21] Risk of cancer in patients receiving insulin glargine
    Dawson, Leslie K.
    Hamilton, Leslie A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (23) : 2025 - 2031
  • [22] Insulin glargine
    Bolli, GB
    Owens, DR
    LANCET, 2000, 356 (9228): : 443 - 445
  • [23] Insulin glargine
    Campbell, RK
    White, JR
    Levien, T
    Baker, D
    CLINICAL THERAPEUTICS, 2001, 23 (12) : 1938 - 1957
  • [24] Insulin Glargine
    Peter S. Gillies
    David P. Figgitt
    Harriet M. Lamb
    Drugs, 2000, 59 : 253 - 260
  • [25] Insulin glargine
    Gillies, PS
    Figgitt, DP
    Lamb, HM
    DRUGS, 2000, 59 (02) : 253 - 260
  • [26] Efficacy of Insulin Glargine Plus 1 Injection of Insulin Glulisine in Patients with Type 2 Diabetes Inadequately Controlled by Insulin Glargine
    Charpentier, Guillaume
    DIABETES, 2014, 63 : A237 - A237
  • [27] A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
    Ito, Hiroyuki
    Tsugami, Emiko
    Ando, Shigenori
    Araki, Rie
    Matsumoto, Suzuko
    Uemura, Kosuke
    Nishio, Shinya
    Antoku, Shinichi
    Yamasaki, Tomoko
    Mori, Toshiko
    Togane, Michiko
    JOURNAL OF DRUG ASSESSMENT, 2018, 7 (01) : 54 - 60
  • [28] INSULIN GLARGINE BIOSIMILAR (GP40061) SHOWS SIMILAR PHARMAKOKINENITICS AND PHARMACODYNAMICS AS COMPARED TO THE REFERENCE DRUG
    Mosikian, A.
    Makarenko, I.
    Avdeeva, O.
    Belikova, T.
    Lunev, I.
    Drai, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A92 - A92
  • [29] Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)
    Pitlick, Jamie M.
    Bryant, Ginelle A.
    Daly, Michael W.
    Koenigsfeld, Carrie F.
    Lehman, Nicholas
    Brueggen, Kaitlin
    McCormick, Alex
    Wellington, Katlynn
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (09) : 846 - 851
  • [30] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
    Kuroda, Akio
    Tsuruo, Miho
    Takeshi, Kondo
    Aki, Nanako
    Oguro, Yukari
    Endo, Itsuro
    Aihara, Ken-ichi
    Tamaki, Motoyuki
    Matsumoto, Toshio
    Matsuhisa, Munehide
    DIABETES, 2014, 63 : A232 - A232
12345